These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7593435)

  • 41. Sandostatin LAR in acromegalic patients: a dose-range study.
    Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.
    Paisley AN; Roberts ME; Trainer PJ
    Clin Endocrinol (Oxf); 2007 May; 66(5):723-6. PubMed ID: 17388793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.
    Chieffo C; Cook D; Xiang Q; Frohman LA
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4047-54. PubMed ID: 23969184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.
    Stolk MF; van Erpecum KJ; Koppeschaar HP; de Bruin WI; Jansen JB; Lamers CB; van Berge Henegouwen GP
    Gut; 1993 Jun; 34(6):808-13. PubMed ID: 8314514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.
    Ho PJ; Boyajy LD; Greenstein E; Barkan AL
    Dig Dis Sci; 1993 Feb; 38(2):309-15. PubMed ID: 8425442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of short-term octreotide therapy and total parenteral nutrition on the development of biliary sludge and lithiasis.
    Baudet S; Medina C; Vilaseca J; Guarner L; Sureda D; Andreu J; Malagelada JR
    Hepatogastroenterology; 2002; 49(45):609-12. PubMed ID: 12063951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
    Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
    J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly.
    Atmaca A; Erbas T
    Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):340-3. PubMed ID: 15977102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gallstone disease: Microlithiasis and sludge.
    Jüngst C; Kullak-Ublick GA; Jüngst D
    Best Pract Res Clin Gastroenterol; 2006; 20(6):1053-62. PubMed ID: 17127187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histopathological improvement of acromegalic cardiomyopathy by intermittent subcutaneous infusion of octreotide.
    Nishiki M; Murakami Y; Sohmiya M; Koshimura K; Inoue K; Goto Y; Nakamura N; Kato Y
    Endocr J; 1997 Oct; 44(5):655-60. PubMed ID: 9466320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up.
    Schmidt K; Althoff PH; Harris AG; Prestele H; Schumm-Draeger PM; Usadel KH
    Pain; 1993 May; 53(2):223-227. PubMed ID: 8336992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report.
    Sheehan MT; Nippoldt TB
    Pituitary; 2000 Dec; 3(4):227-30. PubMed ID: 11788010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Octreotide stimulates Ca++ secretion by the gallbladder: a risk factor for gallstones.
    Moser AJ; Giurgiu DI; Morgenstern KE; Abedin ZR; Roslyn JJ; Abedin MZ
    Surgery; 1999 May; 125(5):509-13. PubMed ID: 10330939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly.
    McKnight JA; McCance DR; Crothers JG; Atkinson AB
    BMJ; 1989 Sep; 299(6699):604-5. PubMed ID: 2508821
    [No Abstract]   [Full Text] [Related]  

  • 55. Octreotide is effective in acromegaly but often results in cholelithiasis.
    Daughaday WH
    Ann Intern Med; 1990 Feb; 112(3):159-60. PubMed ID: 2404444
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of long term octreotide on gall stone formation and gall bladder function.
    Bigg-Wither GW; Ho KK; Grunstein RR; Sullivan CE; Doust BD
    BMJ; 1992 Jun; 304(6842):1611-2. PubMed ID: 1628089
    [No Abstract]   [Full Text] [Related]  

  • 57. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis.
    Roti E; Minelli R; Gardini E; Salvi M; Bianconi L; Balducci L; Manfredi A; Braverman LE
    J Endocrinol Invest; 1990 Jan; 13(1):69-72. PubMed ID: 2319110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Slow intestinal transit and gallstone formation.
    Hussaini SH; Pereira SP; Dowling RH; Wass JA
    Lancet; 1993 Mar; 341(8845):638. PubMed ID: 8094871
    [No Abstract]   [Full Text] [Related]  

  • 59. Pancreatic exocrine and gallbladder function during long-term treatment with octreotide (SMS 201-995).
    Hopman WP; van Liessum PA; Pieters GF; Smals AG; Tangerman A; Jansen JB; Rosenbusch G; Lamers CB; Kloppenborg PW
    Digestion; 1990; 45 Suppl 1():72-6. PubMed ID: 2185969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proceedings of the discussion, "Tolerability and safety of Sandostatin".
    Wass JA; Popovic V; Chayvialle JA
    Metabolism; 1992 Sep; 41(9 Suppl 2):80-2. PubMed ID: 1518439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.